FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Autres langues Frazier Lifesciences Acquisition Corporation

Actions

NAMS

NL00150012L7

Temps réel estimé Tradegate Autres places de cotation 16:21:03 15/05/2024			Varia. 5j.	Varia. 1 janv.
18,4 ^EUR	-8,96 %		-8,96 %	+80,93 %

14:57	FRAZIER LIFESCIENCES ACQUISITION CORPORATION : TD Cowen toujours positif	ZM
08/05	NewAmsterdam Pharma Company N.V. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	09/05
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	09/05
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	27/03
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	25/03
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	12/03
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	12/03
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops	28/02
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Frazier Lifesciences Acquisition Corporation

Actions

NAMS

NL00150012L7

Autres langues

Filtres